In the Phase 2 clinical trial published in The New England Journal of Medicine in 2023, gastrointestinal side effects affected the majority of participants, with nausea, vomiting, diarrhea, and constipation being the most frequent complaints
Some individuals experience reflux during dose escalation phases, while others notice symptoms level off as their bodies adapt over 4-8 weeks
Ipamorelin selectively stimulates growth hormone release without affecting ACTH or cortisol levels, offering a safer alternative for performance and therapeutic use. Patel et al., Journal of Endocrinology This makes Ipamorelin especially attractive for users who want the benefits of increased GHsuch as muscle growth , fat loss , joint repair , and anti-aging effects without the side effects of systemic hormone disruption
It helps confirm sequence accuracy, detect impurities, and identify degradation products